# SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

> **NCT03433183** · PHASE2 · COMPLETED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 21 (actual)

## Conditions studied

- Malignant Peripheral Nerve Sheath Tumors
- Neurofibromatosis 1

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT03433183
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-02
- **Primary completion:** 2022-06-22
- **Final completion:** 2023-10-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03433183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03433183, "SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03433183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*